What's New in Pediatric Dermatology?
December 2017
in “
Annales de dermatologie et de vénéréologie
”
alopecia areata JAK inhibitors hair regrowth adalimumab methotrexate genetic mosaicism propranolol sirolimus olumacostat glasaretil neurofibromatosis type 1 café au lait spots hyperthermia HPV ichthyosis Th17-dominant inflammation anti-IL-17 therapies Jakafi Humira Trexall Inderal Rapamune NF1 human papillomavirus interleukin-17
TLDR In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.
The document reviewed recent advancements in pediatric dermatology as of 2017. Key findings included a comprehensive analysis of 541 trials on atopic dermatitis treatments, highlighting the efficacy of dermocorticoids and inhibitors. For alopecia areata, JAK inhibitors showed promise in case series, with 4 out of 6 children experiencing significant hair regrowth. Psoriasis research included a study comparing adalimumab and methotrexate in 114 children, while genetic mosaicism was confirmed in various skin conditions, influencing treatment approaches. Propranolol was effective for problematic hemangiomas in a study of 51 infants. Sirolimus showed modest to significant improvement in 19 patients with resistant lymphatic malformations. A new acne treatment, olumacostat glasaretil, was evaluated in a randomized trial with 108 patients, showing potential. For neurofibromatosis type 1, a decision tree was developed based on a study of 419 children with café au lait spots. Additionally, a flavored spray improved medication adherence in a small study of 25 children. Hyperthermia was found to enhance antiviral responses in HPV-infected cells. Lastly, a study on ichthyosis revealed a Th17-dominant inflammation, suggesting future trials with anti-IL-17 therapies.